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Abstract Background. Liver transplantation for type 
IV glycogen storage disease (branching-enzyme deficien-
cy) results in the resorption of extrahepatic deposits of 
amylopectin, but the mechanism of resorption is not 
known. 
Methods. We studied two patients with type IV glyco-
gen storage disease 37 and 91 months after liver trans-
plantation and a third patient with lysosomal glucocerebro-
sidase deficiency (type 1 Gaucher's disease), in whom 
tissue glucocerebroside deposition had decreased 26 
months after liver replacement, to determine whether the 
migration of cells from the allograft (microchimerism) 
could explain the improved metabolism of enzyme-defi-
cient tissues in the recipient. Samples of blood and biopsy 
specimens of the skin, lymph nodes, heart, bone marrow, 
or intestine were examined immunocytochemically with 
the use of donor-specific monoclonal anti-HLA antibodies 
and the polymerase chain reaction, with preliminary ampli-
fication specific to donor alleles of the gene for the beta 
I N patients with type IV glycogen storage disease, deficiency of the branching enzyme alpha-l,4-glu-
can:alpha-l,4-g1ucan 6-glucosyltransferase is respon-
sible for the accumulation in the liver and elsewhere of 
an insoluble and irritating amylopectin-like polysac-
charide.! We recently described the absorption of this 
amylopectin from the extrahepatic tissues after liver 
transplantation,2leading Howell to predict that an ex-
planation of the benefit would "clearly teach us a 
great deal about transplantation.,,3 That prediction 
has been shown to be accurate by our observation in 
this study that patients with type IV glycogen storage 
disease in whom liver transplantation was successful 
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chain of HLA-DR molecules, followed by hybridization with 
allele-specific oligonucleotide probes. 
Results. Histopathological examination revealed that 
the cardiac deposits of amylopectin in the patients with 
glycogen storage disease and the lymph-node deposits of 
glucocerebroside in the patient with Gaucher's disease 
were dramatically reduced after transplantation. Immuno-
cytochemical analysis showed cells containing the HLA 
phenotypes of the donor in the heart and skin of the pa-
tients with glycogen storage disease and in the lymph 
nodes, but not the skin, of the patient with Gaucher's dis-
ease. Polymerase-chain-reaction analysis demonstrated 
donor HLA-DR DNA in the heart of both patients with gly-
cogen storage disease, in the skin of one of them, and in 
the skin, intestine, blood, and bone marrow of the patient 
with Gaucher's disease. 
Conclusions. Systemic microchimerism occurs after 
liver allotransplantation and can ameliorate pan cellular 
enzyme deficiencies. (N Engl J Med 1993;328:745-9.) 
became chimeras: the cells of the host organs became 
mixed with cells of the donor genome that had migrat-
ed from the allograft into the tissues of the recipient 
and apparently served as enzyme carriers. We also 
found evidence of similar chimerism and consequent 
metabolic benefits after liver transplantation in a pa-
tient who had type I Gaucher's disease, a disorder 
caused by a deficiency of the lysosomal enzyme beta-
gl ucocere brosidase. 4 
CASE REPORTS 
Patients 1 and 2 (Type IV Glycogen Storage Disease) 
In April 1992, biopsy specimens of liver, endomyocardium, and 
skin were obtained from Patients I and 2, two brothers with type 
IV glycogen storage disease who had undergone liver replacement 
for hepatic failure 91 and 37 months earlier.z The patients were 31 
and 20 months old at the time of transplantation and were subse-
quently treated with cyclosporine and prednisone. Their physical 
and intellectual development has been steady since the operation. 
Patient 3 (Type 1 Gaucher's Disease) 
The diagnosis of type 1 Gaucher's disease in Patient 3 (who was 
20 years old in 1992) was proved by biopsy of a lytic lesion on the 
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femoral neck of his left leg at the age of 4 yea rs, and was confirmed 
by study of his spleen, which was removed at th e age of 6. From 
1979 to 1982 he was treated every six to eight weeks with unmodified 
human placenta l gJucocerebrosidase (8 unit s per kilogram of body 
weight intravenous ly) a t the National Institutes of H ea lth . From 
November 1989 to january 1990 he was treated every two weeks 
with mac rophage- targe ted human placenta l g lucocerebros idase (30 
un its per kilogram intravenously; Ceredase , Genzyme, Cambridge, 
Mass. ) There was no evidence of benefit during either period of 
enzyme trea tment. 
Because of hepa tic failure and recurrent bleeding from esoph-
ageal varices, the patient underwent orthotopic liver transplan-
tation in April 1990. Thereafter, he was treated with FK 506 
and prednisone. His liver function has been normal since then , 
and hi s severe preexisting muscle weakness has s teadily improved. 
In july 1990, three months after liver transpla ntation , enzyme 
treatment was resumed. In june 1992, 26 months after li ve r re-
placement , biopsy speci mens were obtained from the a llograft, 
skin, lymph node, jejunum (by endoscopy)' and iliac-crest bone 
marrow. 
METHODS 
The transplantation and biopsy procedures were considered es-
sential for optimal care of all three patients and were performed 
with their parents' consent. Tissues were fixed in 10 percent forma-
lin for conventional st'-lining and frozen in Optimu m Cold Tempera-
ture medium (OCT, Tissue-Tek, Ames Divis ion, Miles La borato-
ries , Elkhart , Ind .) for immunocy tochemica l eva luat ion or in liquid 
nitrogen for D NA typing. Gaucher's cells and amylopectin inclu-
sions were examined by lig ht microscopy a fter staining: with period-
ic acid - Schiff sta in (PAS) with and without di as tase digestion 
( PAS- D ). 
Immunocytochemical Evaluation 
The HLA types of the three donors were determined at the time 
of organ procurement (September 1984 in the donor for Patient I , 
March 1989 in the donor for Patient 2, and April 1990 in the donor 
for Pa tie nt 3). The HLA types of the recipients were determined 
just before transpl an tat ion. After invest iga tors established which 
class I and class 11 antigens were present in the donor but not in the 
recipient, monoclonal antibodies we re chosen from a library (w hose 
sources were American Tissue and Cell Culture, Genetic Synterus, 
Seattle, and One Lambda, Canoga Park , Calif.) and used for pheno-
typing of the biopsy specimens by ind irect immunofluoresce nce and 
immunoperox idase (avidin - biotin complex ) methods . The liver re-
moved at the time of transplantation was used as a nega tive control 
for donor-specific antibodies; as an additional negative-control 
measure, staining was ca rried out with irrelevant anti -HLA anti-
bodies and omission of the primary antibody. Live rs with known 
HLA phenotypes sta ined with mat ching an ti -HLA monoclonal 
antibodies were used as pos itive contro ls. 
Polymerase Chain Reaction 
Molecular typing o f the beta chain of HLA-DR molecules was 
performed with use of the po lymerase chain react ion, according to 
the protocol of the II th International Histocompatib ility Work-
shop, ' in which preliminary amplification of the HLA-DR bcta-
chain gene is performed before allele-specific am plification. 
RESULTS 
Histologic Studies 
Patients with Glycogen Storage Disease 
In the patients with glycogen storage disease nei -
ther of the liver allografts had evidence of rejection or 
amylopectin deposition. At the time of our pr vious 
report on these patients,2 the area of heart tissue re-
placed by amylopec tin in the younger brother (Patient 
2) had decreased from 13 to 6 percent 14 months after 
transplan tation. A furt her reduction to less than I per-
cent occurred during the ensuing 22 months (Fig. I ). 
A 
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Figure 1. Endomyocardial Tissue from Patient 2, with Type IV 
Glycogen Storage Disease. 
Panel A, a photomicrograph of a specimen obtained at biopsy in 
April 1989, three weeks after liver transplantation, reveals diffuse 
amylopectin deposition (dark red) in the myocytes (PAS-D with 
formalin fixation, X250). In Panel S, a specimen obtained in April 
1992, there are only traces of amylopectin (arrow) (PAS-D with 
formalin fixation of frozen tissue, x 250). 
The heart of the older brother (Patient I) was almost 
free of amylopectin when the first biopsy was per-
formed , more than 5 years after transplantation2; it 
appeared the same 91 months after transplantation. 
Patient with Gaucher's Disease 
A hilar lymph node removed with the native liver 
from the patient with Gaucher's disease in April 1990 
contained numerous glucocerebroside-filled cells that 
profoundly distorted the nodal architecture. An in-
guinal lymph node removed 26 months later con-
tained only a few of these cells, located predominantly 
in the medullary sinuses (Fig. 2). A biopsy of the al -
lograft performed 26 months after transplantation 
showed that the architecture of the graft was intact , 
with no evidence of rejection and only a few Gaucher's 
cells scattered in the sinusoids . Specimens of the skin 
and small intestine were normal, and the bone marrow 
contained only very few Gaucher's cells. 
Immunocytochemical Studies 
The end othelium and bile ducts of all three patients 
retained the phenotypes of the donors , whereas most 
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Figure 2. Sections of Lymph Nodes from Patient 3, with Type 1 Gaucher's Disease. 
Before transplantation (Panel A), a hepatic hilar lymph node resected with the diseased liver in April 1990 shows marked architectural 
distortion because of massive deposition of glucocerebroside in Gaucher's cells (PAS, xSO). After transplantation (Panel B), an inguinal 
lymph node resected in 1992 for analysis of chimerism shows restoration of the architecture, with occasional Gaucher's cells in the 
sinusoids (PAS, xSO). 
of the KupfTer cells of the liver were replaced by those 
of the recipient, as previously described.6.a 
Cells of the donor phenotype were found in the 
hearts of both patients with glycogen storage disease 
(Table I). These cells constituted a minority of the 
interstitial cardiac cells and were seen at a density of 
8 to 10 cells per square millimeter in ul trathin sections 
(2 J-Lm) (Fig. 3). The vascular endothelial cells of the 
heart were exclusively of the phenotype of the recipi-
ent. The skin of both patients contained donor cells 
interspersed among the cells of the basal layer of epi-
dermis and in the periadventitial tissue of dermal 
blood vessels. All epidermal and vascular endothelial 
cells had the recipient ' s phenotype. Cells with the 
donor's phenotype could be found in the lymph nodes 
but not the skin of the patient with Gaucher's disease 
(Table I). 
Polymerase Chain Reaction 
Chimerism was observed in the hearts of both pa-
tients with glycogen storage disease and in the skin 
of one of them on polymerase-chain-reaction analy-
sis (Table 2). The HLA type of the patient with 
Gaucher's disease was DR2, 7, and that of the donor 
was DRI,II (Table I). When HLA-DRI-specific 
primers and probes were used (Fig. 4), the donor's 
DNA was found in the blood, bone marrow, skin, and 
small bowel of the recipient (Table 2) . 
DISCUSSION 
The resorption of amylopectin from the heart pre-
viously reported after liver transplantation in patients 
with glycogen storage disease2 was confirmed by en-
domyocardial biopsies after additional months of 
follow-up. Donor cells could be detected in the biopsy 
specimens and other tissues of the recipients by im-
munocytochemical and molecular techniques 91 and 
37 months, respectively, after liver replacement. Simi-
lar donor cells were also found in the skin, lymph 
nodes, small bowel, bone marrow, and blood of a 
patient with Gaucher's disease. 
We have proposed elsewhere6,9,IO that the success-
ful engraftment of all whole-organ transplants con-
notes (and requires) an exchange between the organ 
and the recipient of cells of lymphocyte-macrophage 
lineage. Although the same process occurs with all 
organs, the high density and quality of the migratory 
cells leaving the liver or coming to it from the re-
cipient are thought to be the basis for the "immuno-
logic privilege" of a hepatic graft,6,9,IO including its so-
called tolerogenicity in other organs from the same 
donor .11 
The bone marrow-derived dendritic (antigen pre-
senting) cells delineated by Steinman and Cohn l2 that 
are normally associated with the induction of T-cell 
Table 1. Features of Chimerism Demonstrated by 
Immunocytochemical Evaluation in Recipients of 
Uver Grafts for Type IV Glycogen Storage Disease 
(Patients 1 and 2) and Type 1 Gaucher's Disease 
(Patient 3). 
FEATUItE PATIENT I PATIENT 2 PA Ti ENT 3 
Reactivity for anti-donor 
HLA antibody' 
No. positive/no. tested 215 2/5 2/2 
Site 
Native liver NT 
Allograft +++ +++ ++ 
Skin + /rare +/rare 
Heart + + NT 
Lymph node NT NT + 
HLA specificities 
Recipient 
A 31, 32 2, 3 1 2 -
B 50 , 61 50,4 1 44,50 
Bw 6 6 4. 6 
DR 7, \I 2, 7 2, 7 
Donort 
A 2, 26 I . - 3 , 31 
B 51, 27 7 , 8 39, 35 
Bw 4 6 
DR:!: I, 6( 13) 6(1 3), 6( 14) I. \I 
*Reactivi ty ranged from "rare" to "++ + "; a minus s ign denotes no 
reaclion. NT denotes nOI tesfed . 
tAlleles in boldface type are Ihose recognized by monoclonal alll ibodies . 
me numbers in parentheses are the antigen subspecificities (spli ts) of 
the broader specificilies . 
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Figure 3. Immunocytochemical Analysis of Heart, Transplanted Liver, and Native Liver in Patient 1, with Type IV Glycogen Storage 
Disease. 
In Panel A, green fluorescence identifies cells with the donor's phenotype (HLA-DR1 ,4; arrows) in the interstitium of the heart (x 1000). 
PanelS shows positive green-staining cells (HLA-DR1 ,4) in the transplanted liver (X400). Panel C (negative control) shows the absence 
of donor (HLA-DR1 A-positive) cells in the recipient's native liver (X400). All sections were stained with a single monoclonal antibody 
specific for HLA-DR1 and DR4. The yellow globules are autofluorescent intracellular pigment. 
immuni ty rather than the induction of tolerance l3,14 
are thought to be the most prominent of the migratory 
cells moving from the liver to distant host tissues, with 
r placement by similar cells of the recipient that home 
to the graft. The distribution of the donor cells is simi-
lar to their distribution after bone marrow transplan-
tat ion.6,15,16 T he consequent chimerism explains why 
the liver allograft can cause graft-versus-host dis-
ease. I 7-20 
T he occu rrence of cell migration after liver trans-
plan tation explains why patien ts with lysosomal stor-
age disorders - Wolman's d isease,21 Niemann-Pick 
disease,22 Gaucher's d isease,23 and the sea-blue histio-
cyte synd rome (unpublished data ) - receive more 
benefi t from liver replacement than simply improved 
hepatic function 24 We had assumed that the lysoso-
mal storage disorder of our patient with Gaucher's 
disease wo uld progress after transplantation, prompt-
ing us to resume enzyme therapy; we now suspect 
that such trea tment was unnecessary. For the absorp-
tion of the intracellular and extracellular amylopec-
tin deposits of type IV glycogen storage disease, as 
well as the intracellular glucocerebroside deposits of 
Gaucher's d isease, it is necessary for the enzyme pro-
d uced by the donor cells to gain access to the sub-
strate. Evidence from in vitro coculture experiments 
suggests that once the donor cells have moved to the 
appropriate location, an enzyme can be transported 
from normal to abnormal cells .25 The number of allo-
geneic cells required to produce a metabolic effect ap-
pears from our results to be surprisingly low. The 
presumed transmission of enzymes from a small to 
a larger cell population raises intriguing questions 
about the potential cell-to-cell transfer of other mole-
cules , including those involved in immunologic proc-
esses. 
With the fuller understanding of what is actually 
accomplished by liver transplanta tion, past conclu-
sions about the mechanisms of inborn errors of me-
tabolism that were deduced from studies of liver-
transplant recipients will require reexamination . For 
Table 2. Distribution of Donor HLA-DR Alleles in the Three Liver 
Recipients, According to Polymerase-Chain-Reaction Analysis. 
PATIENT 
No. 
2 
3 
DoNOR-SPECIFIC 
ALlEL L 
DR! 
DR6 
DR! 
DISTRIBUTiON* 
SMAll 
LI VER SKJN HEART BLOOD MARROW BOWEL 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
NT + 
NT 
NT 
+ 
NT 
NT 
+ 
*The li ver tissue wa~ from the donorS ; aU other tissues were from the reci pienls. A plus sign 
de notes the presence of a donor-spec ific allele. and a minus sign its abs~nccK NT denotes not 
lCs ted . 
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Figure 4. Demonstration 01 Donor DNA after Transplantation in 
Patient 3, with Type 1 Gaucher's Disease. 
Genomic DNA was extracted from the recipient's tissues and 
amplilied with HLA-DR beta-chain "generic" oligonucleotide prim-
ers to determine the subgroup of the donor's alleles. "Specific' 
primers were then used to amplify the alleles selectively. The 
alleles were identified by hybridizing the amplified DNA to radiola-
beled allele-specific probes. After HLA-DR1-specific amplifica-
tion of DNA from the liver, blood, bone marrow, skin, and small 
bowel, the DNA was separated by electrophoresis on an agarose 
gel and then analyzed by Southern blotting. The denatured DNA 
present on the nylon membrane was hybridized to a labeled HLA-
DR1 (donor)-specilic ol igonucleotide probe. For liver DNA, the 
quantity analyzed was reduced to 1 percent of the other samples. 
Although lower in intensity, the signal from donor DNA in the small 
bowel was clearly positive in the original film, although this can be 
seen only faintly . The negative control was a reaction run without 
DNA (last lane). 
example, the decline in serum cholesterol concentra-
tions after liver transplantation in patients with famil-
ial hypercholesterolemia26 that was ascribed to the 
low-density lipoprotein receptors of the allograft hep-
atocytes27 may reflect in part the presence of these 
receptors on widely disseminated donor cells that are 
not hepatocytes. Migratory Kupffer cells alone ac-
count for 10 to 15 percent of all cells in the liver and 
one fifth of the lotal hepatic lysosomal volume.28 
If, as we have proposed ,6,9,IO microchimerism differ-
ing only in degree is an integral feature of the success-
ful engraftment of any organ, all such transplantation 
procedures could result in a gain in metabolic func-
tion. This could explain the report by Desnick et al 29 
that native kidneys that had failed as a result of the 
accumulation of glycosphingolipid in a patient with 
Fabry's disease recovered their function after success-
ful renal transplantation. 
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